Statement: 1 patient in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 3/22 (13.64%)   ascites with hyponatraemia 0/22 (0.00%)   febrile neutropenia with respiratory infection 1/22 (4.55%)   urosepsis 1/22 (4.55%)   febrile neutropenia with urinary tract infection 0/22 (0.00%)   dyspnoea 1/22 (4.55%)   hypoxia 0/22 (0.00%)   thromboembolism 0/22 (0.00%) Adverse Events 2:   Total: 4/17 (23.53%)   ascites with hyponatraemia 1/17 (5.88%)   febrile neutropenia with respiratory infection 0/17 (0.00%)   urosepsis 0/17 (0.00%)   febrile neutropenia with urinary tract infection 1/17 (5.88%)   dyspnoea 0/17 (0.00%)   hypoxia 1/17 (5.88%)   thromboembolism 1/17 (5.88%)
Secondary_evidence: Adverse Events 1:   Total: 9/46 (19.57%)   Febrile neutropenia 1/46 (2.17%)   Cardiac disorder 1/46 (2.17%)   Diarrhea 1/46 (2.17%)   Upper gastrointestinal hemorrhage 1/46 (2.17%)   Chest pain 1/46 (2.17%)   Fatigue 1/46 (2.17%)   Neutrophil count decreased 2/46 (4.35%)   Platelet count decreased 1/46 (2.17%)   Anorexia 1/46 (2.17%)   Dehydration 1/46 (2.17%)   Serum potassium increased 1/46 (2.17%)